Composite local low-rank structure in learning drug sensitivity.

The molecular characterization of tumor samples by multiple omics data sets of different types or modalities (e.g. gene expression, mutation, CpG methylation) has become an invaluable source of information for assessing the expected performance of individual drugs and their combinations. Merging the relevant information from the omics data modalities provides the statistical basis for determining suitable therapies for specific cancer patients. Different data modalities may each have their specific structures that need to be taken into account during inference. In this paper, we assume that each omics data modality has a low-rank structure with only few relevant features that affect the prediction and we propose to use a composite local nuclear norm penalization for learning drug sensitivity. Numerical results show that the composite low-rank structure can improve the prediction performance compared to using a global low-rank approach or elastic net regression.

[1]  A. Lusis,et al.  Considerations for the design of omics studies , 2017 .

[2]  Tero Aittokallio,et al.  Machine learning and feature selection for drug response prediction in precision oncology applications , 2018, Biophysical Reviews.

[3]  A. Roslani,et al.  Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro , 2017, In Vitro Cellular & Developmental Biology - Animal.

[4]  Joel Greshock,et al.  Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.

[5]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[6]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[7]  Krister Wennerberg,et al.  Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach , 2017, Bioinform..

[8]  Tero Aittokallio,et al.  Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization , 2016, Bioinform..

[9]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[10]  Nci Dream Community A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[11]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[12]  Xiaokang Liu,et al.  Integrative multi‐view regression: Bridging group‐sparse and low‐rank models , 2019, Biometrics.

[13]  M. Stratton,et al.  Abstract 2206: Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. , 2013 .

[14]  Zhi Zhao,et al.  Structured penalized regression for drug sensitivity prediction , 2019, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[15]  D G Hoel,et al.  Fundamental carcinogenic processes and their implications for low dose risk assessment. , 1976, Cancer research.

[16]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.